全文获取类型
收费全文 | 126574篇 |
免费 | 9722篇 |
国内免费 | 6597篇 |
专业分类
耳鼻咽喉 | 690篇 |
儿科学 | 2544篇 |
妇产科学 | 1874篇 |
基础医学 | 22883篇 |
口腔科学 | 2161篇 |
临床医学 | 8812篇 |
内科学 | 19302篇 |
皮肤病学 | 1891篇 |
神经病学 | 13998篇 |
特种医学 | 2042篇 |
外国民族医学 | 46篇 |
外科学 | 7298篇 |
综合类 | 19918篇 |
现状与发展 | 29篇 |
一般理论 | 1篇 |
预防医学 | 4615篇 |
眼科学 | 1645篇 |
药学 | 16891篇 |
9篇 | |
中国医学 | 2778篇 |
肿瘤学 | 13466篇 |
出版年
2024年 | 151篇 |
2023年 | 1319篇 |
2022年 | 1964篇 |
2021年 | 3777篇 |
2020年 | 3305篇 |
2019年 | 3253篇 |
2018年 | 3256篇 |
2017年 | 3446篇 |
2016年 | 3831篇 |
2015年 | 4221篇 |
2014年 | 6636篇 |
2013年 | 8888篇 |
2012年 | 6855篇 |
2011年 | 8215篇 |
2010年 | 6797篇 |
2009年 | 6940篇 |
2008年 | 7512篇 |
2007年 | 7441篇 |
2006年 | 6777篇 |
2005年 | 6159篇 |
2004年 | 5636篇 |
2003年 | 5053篇 |
2002年 | 4268篇 |
2001年 | 3809篇 |
2000年 | 3306篇 |
1999年 | 2808篇 |
1998年 | 2814篇 |
1997年 | 2456篇 |
1996年 | 2023篇 |
1995年 | 1647篇 |
1994年 | 1421篇 |
1993年 | 1155篇 |
1992年 | 865篇 |
1991年 | 766篇 |
1990年 | 588篇 |
1989年 | 473篇 |
1988年 | 389篇 |
1987年 | 342篇 |
1986年 | 345篇 |
1985年 | 424篇 |
1984年 | 343篇 |
1983年 | 206篇 |
1982年 | 281篇 |
1981年 | 217篇 |
1980年 | 164篇 |
1979年 | 101篇 |
1978年 | 73篇 |
1977年 | 52篇 |
1976年 | 43篇 |
1975年 | 36篇 |
排序方式: 共有10000条查询结果,搜索用时 20 毫秒
61.
62.
63.
《Clinical therapeutics》2019,41(5):836-847
PurposeA role for the immune system in causing myalgic encephalopathy/chronic fatigue syndrome (ME/CFS) is long suspected, but few studies have looked for specific autoantibodies that might contribute to the symptoms. Our aim was to look for evidence of antibodies to neuronal proteins in patients with ME/CSF.MethodsSera samples from 50 patients and 50 healthy individuals were sent coded to the Neuroimmunology Laboratory in Oxford. Screening for antibody binding to neuronal tissue was performed on brain tissue and neuronal cultures. Specific serum antibodies were assessed by antigen-specific cell-based assays and radioimmunoassays. After antibody testing, the associations between seropositive status and clinical data were investigated.FindingsOverall, 8 patients and 11 participants were found to have some serum immunoreactivity toward neuronal or neuromuscular junction proteins, but only 1 patient and 2 participants had specific serum antibodies. Nevertheless, seropositive status in patients with ME was associated with shorter duration since onset and a more severe disease.ImplicationsThe results indicate no overall increased frequency of antibodies to neuronal proteins in ME/CSF and no evidence of a specific antibody that might be causative or contribute to clinical features in patients. However, the association of seropositive status with shorter duration of disease and more severe symptoms suggests a possible role of antibodies at onset in some patients and should be the focus of future studies. 相似文献
64.
胆碱能抗炎通路是一条神经免疫通路,主要依靠乙酰胆碱与巨噬细胞及其他细胞表面上的α7nAchR相结合抑制促炎因子的合成与释放,从而防止组织损伤。α7nAchR是胆碱能递质的主要受体,在胆碱能抗炎通路中起关键作用。针刺治疗有明确的抗炎作用,其作用机制可能与调控α7nAchR激活胆碱能抗炎通路有关。近年来虽然国内外学者对针刺抗炎机制进行了大量研究,然而针刺抗炎的作用机制目前仍不明确。该文从胆碱能抗炎通路概述、α7nAchR结构及功能、α7nAchR的分布、α7nAchR在胆碱能抗炎通路的作用、针刺调控α7nAchR激活胆碱能抗炎通路的机制等方面对针刺调控α7nAchR激活胆碱能抗炎通路进行分析总结,为今后探究针刺抗炎作用机制提供借鉴思路和科学依据。 相似文献
65.
《Cancer cell》2021,39(11):1497-1518.e11
66.
C. Banella M. Ginevrino G. Catalano E. Fabiani G. Falconi M. Divona P. Curzi P. Panetta M.T. Voso N.I. Noguera 《Hematology/oncology and stem cell therapy》2021,14(2):163-168
FGFR–TACC, found in different tumor types, is characterized by the fusion of a member of fibroblast grown factor receptor (FGFR) tyrosine kinase (TK) family to a member of the transforming acidic coiled-coil (TACC) proteins. Because chromosome numerical alterations, hallmarks of FGFR–TACC fusions are present in many hematological disorders and there are no data on the prevalence, we studied a series of patients with acute myeloid leukemia and myelodysplastic syndrome who presented numerical alterations using cytogenetic traditional analysis. None of the analyzed samples showed FGFR3–TACC3 gene fusion, so screening for this mutation at diagnosis is not recommended. 相似文献
67.
68.
69.
Wilbert S Aronow 《Expert opinion on pharmacotherapy》2016,17(2):205-215
Introduction: It is important to know how to treat hypertension in patients with coronary artery disease (CAD). The reason for the review was to update this treatment and to discuss the 2015 American Heart Association/American College of Cardiology/American Society of Hypertension 2015 guidelines of treatment of hypertension in patients with CAD.Areas covered: Studies between 1968 and 2015 were reviewed on treatment of hypertension in patients with CAD using a Medline search, and studies between 1977 and 2015 were reported. Hypertension should be treated with beta blockers and ACE inhibitors or angiotensin receptor blockers (ARBs). Long-acting nitrates are effective antianginal and anti-ischemic drugs. Calcium-channel blockers (CCBs) may be added if angina persists despite beta blockers and long-acting nitrates. The 2015 guidelines recommend that the blood pressure should be < 140/90 mm Hg in patients aged ≤ 80 years and the systolic blood pressure < 150 mm Hg if they are ≥ 80 years.Expert opinion: Hypertension in patients with CAD should be treated with beta blockers and ACE inhibitors or ARBs. Long-acting nitrates are effective antianginal and anti-ischemic drugs. CCBs may be added if angina persists despite beta blockers and long-acting nitrates. The blood pressure should be < 140/90 mm Hg in patients aged < 80 years and the systolic blood pressure < 150 mm Hg if they are ≥ 80 years. 相似文献
70.